Healthcare tech group Mediware Information Systems said it tapped former United-Health Group subsidiary OptumInsight chief exec Bill Miller as its new CEO, replacing Kelly Mann, who has served in the corner office since 2007.
Mediware said that Miller will work with the Lenexa, Kansas-based company’s management to “build and accelerate the company’s platform” to expand its footprint in the alternate care and human and social services market.
“I want to thank the team at Mediware for their dedication, innovation, and hard work over the last several years. Mediware is a best-in-class company and it’s been a privilege to have played a leading role. Bill is an accomplished industry executive with valuable operational skills and creative insights. With his leadership and the ongoing support of our partners at TPG, I am confident that Mediware is well positioned for its next chapter of growth,” former CEO Mann said in a press release.
Miller has more than 20 years of experience in healthcare and technology, and during his time at OptumInsight saw revenues grow from $1.5 billion to $5 billion. Prior to his time at OptumInsight, Miller served as tech VP at Cerner.
“Having spent my entire career in the healthcare and technology industries, I have known Mediware as an industry leader with a deep understanding of the marketplace and an ongoing commitment to quality and client service. I am excited about their strong position in the expanding markets they serve, and look forward to working with TPG and the Mediware team to build on the momentum that the company has achieved to-date,” Miller said in a prepared statement.
OrthoAccel Technologies said this week it named former Zimmer Biomet dental GM David Josza as its new CEO, effective August 1.
Josza spent 14 years at Biomet before it was acquired by Zimmer in 2015, when Josza was tapped to lead the acquisition integration, Houston-based OrthoAccel said in a press release.
“OrthoAccel is a market leader in accelerated orthodontic technology and I am delighted to lead the company’s next phase of growth and innovation. This is an exciting stage in OrthoAccel’s trajectory and, based on the feedback of orthodontists and patients who have experienced the new AcceleDent Optima, there is significant opportunity for growth ahead for this best-in-class treatment technology,” Josza said in a prepared statement.
“We are excited to welcome David and recognize that his in-depth experience in dental and medical industries, combined with his many successes as a strategist and business developer, provide an excellent leadership platform for his role at OrthoAccel Technologies,” board chair Brian Smith said in a press release.
JustRight Surgical said yesterday it tapped Robert Kline as its new chief executive, replacing co-founder and CEO Russ Lindemann, who is retiring.
Prior to joining JustRight Surgical, Kline served as prez & CEO of biotech tools company ViroCyt which was acquired by Sartorious AG last July. Kline also served as founder, prez and CEO of Medivance, which was acquired by C.R. Bard in 2011 for $260 million.
“JustRight Surgical is gaining momentum in the marketplace and due to personal considerations, I felt it was an ideal time to reduce my involvement with the company to my Board responsibilities,” Lindemann said in a press release.
“I am excited to join the JustRight team and the opportunity to build upon the exceptional accomplishments of Russ and the founding team,” Kline said in a prepared statement.
Johnson will be leaving to ‘pursue his professional goals that include a career in private equity,” the Warsaw, Ind.-based company said, after having helped with the integration of LDR and the placement of new leaders in the company’s spine and dental business.
Current spine, dental, craniomaxillofacial and thoracic biz finance vp Chris Jefferis will operate as interim group prez until a permanent successor is named, Zimmer Biomet said.
Healthcare, clinical and scientific consulting provider G&L Scientific said today it appointed former Fresenius senior director Brigid Flanagan as its clinical operations VP.
During her time at Fresenius Medical Care North America, Flanngan set up and managed a CRO dedicated specifically to renal research, G&L Scientific said.
“We are very happy that Brigid is joining G&L Scientific. The experience that she has gained over 20-plus years in clinical operations will be extremely valuable to our clients. The fact that G&L was able to attract and secure such a talented and experienced individual speaks volumes for the reputation of our company for delivering world-class services,” CEO Stephen Loughrey said in a press release.